Discover
ONCY
Oncolytics Biotech Inc.
0.80
50 x 0.80
100 x 0.81
bid
ask
+
0.00
0.05%
12:35 PM
timesize
| Ytd | -7.68% | |
| 1y | -7.68% |
0.78
day range
0.81
0.73
52 week range
1.51
| Open | 0.80 | Prev Close | 0.80 | Low | 0.78 | High | 0.81 | Mkt Cap | 80.61M |
| Vol | 363.27K | Avg Vol | 1.35M | EPS | -0.31 | P/E | -2.59 | Forward P/E | -3.02 |
| Beta | 1.13 | Short Ratio | 3.51 | Inst. Own | 1.76% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 0.87 | 200-d Avg | 0.96 | 1yr Est | 4.85 |
| Income Statement | |||
| Operating Expenses | 9.28M | ||
| Research and Development Expense | 4.55M | ||
| Selling, General and Administrative Expense | 4.73M | ||
| Operating Income | -9.28M | ||
| Net Income | -9.24M | ||
| Net Income Common Stock | -9.24M | ||
| Net Income Common Stock (USD) | -9.24M | ||
| Consolidated Income | -9.24M | ||
| Earnings per Basic Share | -0.08 | ||
| Earnings per Basic Share (USD) | -0.08 | ||
| Earnings per Diluted Share | -0.08 | ||
| Earning Before Interest & Taxes (EBIT) | -9.24M | ||
| Earning Before Interest & Taxes (USD) | -9.24M | ||
| Weighted Average Shares | 112.29M | ||
| Weighted Average Shares Diluted | 112.29M | ||
| Balance Sheet | |||
| Cash and Equivalents | 5.49M | ||
| Cash and Equivalents (USD) | 5.49M | ||
| Trade and Non-Trade Receivables | 961.00K | ||
| Current Assets | 7.49M | ||
| Property, Plant & Equipment Net | 674.00K | ||
| Total Assets | 8.16M | ||
| Debt Current | 166.00K | ||
| Total Debt | 508.00K | ||
| Current Liabilities | 5.42M | ||
| Debt Non-Current | 342.00K | ||
| Total Liabilities | 13.29M | ||
| Accumulated Retained Earnings (Deficit) | -438.74M | ||
| Accumulated Other Comprehensive Income | 6.23M | ||
| Shareholders Equity | -5.13M | ||
| Shareholders Equity (USD) | -5.13M | ||
| Assets Non-Current | 674.00K | ||
| Total Debt (USD) | 508.00K | ||
| Liabilities Non-Current | 7.87M | ||
| Trade and Non-Trade Payables | 2.68M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 89.00K | ||
| Net Cash Flow from Financing | 7.61M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 291.00K | ||
| Capital Expenditure | -6.00K | ||
| Issuance (Purchase) of Equity Shares | 7.61M | ||
| Net Cash Flow from Investing | -6.00K | ||
| Net Cash Flow from Operations | -7.29M | ||
| Effect of Exchange Rate Changes on Cash | -24.00K | ||
| Share Based Compensation | 2.30M | ||